Singapore markets closed

Cassava Sciences, Inc. (SAVA)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
10.43+0.86 (+8.93%)
As of 10:25AM EDT. Market open.

Cassava Sciences, Inc.

6801 N. Capital of Texas Highway
Suite 300 Building 1
Austin, TX 78731
United States
512 501 2444

Full-time employees29

Key executives

NameTitlePayExercisedYear born
Mr. Eric J. SchoenChief Financial Officer460kN/A1968
Mr. R. Christopher CookSenior VP, Company Secretary & General Counsel425kN/A1964
Dr. James W. Kupiec M.D.Chief Medical Officer435kN/A1953
Dr. George Thornton Ph.D.Senior Vice President of TechnologyN/AN/AN/A
Mr. Michael ZamlootSenior Vice President of Technical OperationsN/AN/AN/A
Dr. Michael Marsman Pharm.D.Senior Vice President of Regulatory AffairsN/AN/AN/A
Dr. Lindsay H. Burns Ph.D.Senior Vice President of NeuroscienceN/AN/AN/A
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

Corporate governance

Cassava Sciences, Inc.’s ISS governance QualityScore as of 1 July 2024 is 9. The pillar scores are Audit: 10; Board: 9; Shareholder rights: 8; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.